[Assessment of efficacy of the drug litovit as a novel pathogenetic modality in acute virus hepatitis].
To study clinical and laboratory parameters in patients with acute viral hepatitis (AVH) given basic therapy in combination with a novel pathogenetic drug litovit versus ursosan. 155 patients with AVH were divided into three groups: 70 patients of group 1 received basic therapy plus litovit, 10 patients of group 2--basic therapy plus ursosan, 60 patients of group 3--basic treatment only. Litovit was well tolerated. Side effects were absent. Hospital stay and severity of clinical AVH symptoms were significantly less in patients of group 1. Less pronounced were also hyperbilirubinemia, cytolytic and mesenchymal-inflammatory syndromes. Clinical and laboratory parameters in AVH patients treated with adjuvant litovit improve quicker than in those with adjuvant ursosan or basic therapy. Litovit has enterosorptive and hepatoprotective activity. Low cost of vitovit therapy makes the drug applicable in wide practice.